FR3095520B1 - Method for stabilizing a peptide - Google Patents

Method for stabilizing a peptide Download PDF

Info

Publication number
FR3095520B1
FR3095520B1 FR1904400A FR1904400A FR3095520B1 FR 3095520 B1 FR3095520 B1 FR 3095520B1 FR 1904400 A FR1904400 A FR 1904400A FR 1904400 A FR1904400 A FR 1904400A FR 3095520 B1 FR3095520 B1 FR 3095520B1
Authority
FR
France
Prior art keywords
peptide
stabilizing
fluorochrome
reconstitution
derivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1904400A
Other languages
French (fr)
Other versions
FR3095520A1 (en
Inventor
Myriam Taverna
De Lassichere Cédric Crosnier
Duc-Thanh Mai
Markus Otto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud Paris 11
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud Paris 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud Paris 11 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1904400A priority Critical patent/FR3095520B1/en
Publication of FR3095520A1 publication Critical patent/FR3095520A1/en
Application granted granted Critical
Publication of FR3095520B1 publication Critical patent/FR3095520B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne une méthode de stabilisation d’un peptide amyloïde Aβ1-42 comprenant une première étape de reconstitution de ce peptide, une seconde étape de congélation et une dernière étape de dérivation par un fluorochrome. Figure pour l’abrégé : pas de figureThe invention relates to a method for stabilizing an Aβ1-42 amyloid peptide comprising a first step of reconstitution of this peptide, a second step of freezing and a last step of derivation by a fluorochrome. Figure for abstract: no figure

FR1904400A 2019-04-25 2019-04-25 Method for stabilizing a peptide Active FR3095520B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1904400A FR3095520B1 (en) 2019-04-25 2019-04-25 Method for stabilizing a peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1904400 2019-04-25
FR1904400A FR3095520B1 (en) 2019-04-25 2019-04-25 Method for stabilizing a peptide

Publications (2)

Publication Number Publication Date
FR3095520A1 FR3095520A1 (en) 2020-10-30
FR3095520B1 true FR3095520B1 (en) 2022-11-25

Family

ID=68501655

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1904400A Active FR3095520B1 (en) 2019-04-25 2019-04-25 Method for stabilizing a peptide

Country Status (1)

Country Link
FR (1) FR3095520B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
FR2889525A1 (en) * 2005-08-04 2007-02-09 Palumed Sa NOVEL POLYQUINOLINE DERIVATIVES AND THEIR THERAPEUTIC USE.

Also Published As

Publication number Publication date
FR3095520A1 (en) 2020-10-30

Similar Documents

Publication Publication Date Title
MX2021001706A (en) Fused ring compounds.
MX2021007538A (en) Bicyclic derivatives.
PH12016502180A1 (en) Determination of ue band and synchronization capability in dual connectivity
MX2021007540A (en) Bicyclic derivatives.
MX2021000153A (en) Ultrapurified dsba and dsbc and methods of making and using the same.
PH12019500005A1 (en) Method and device for signal detection
WO2020061478A3 (en) Methods for purifying heterodimeric, multispecific antibodies
EA201791489A1 (en) METHOD FOR PROCESSING IMAGE DATA AND DEVICE FOR IMPLEMENTING THIS METHOD
CL2019002232S1 (en) Car.
EA202192786A1 (en) SOLID FORMS of (E)-3-[2-(2-THIENYL)VINYL]-1H-PYRAZOLE
CL2020001201S1 (en) Car.
CL2020000174S1 (en) Car.
MX2021006515A (en) Methylobacterium compositions for improving corn yield.
FR3095520B1 (en) Method for stabilizing a peptide
MX2021004467A (en) Strained acidic reduced carbiohydrate dairy products.
CO2022000748A2 (en) Pyrazolopyrimidine compound, preparation method therefor and its applications
ZA202203000B (en) Image encoding/decoding method and device
MX2023002810A (en) Method of making lyophilized protein formulations.
EP3895430A4 (en) Method for deriving constructed affine merge candidates
CL2020000224S1 (en) Car.
EA202190843A1 (en) INTEGRATED FRAME STRUCTURE FOR MUTUALLY CLUTCHED STRUCTURE BLOCK, MUTUALLY CLUTCHED STRUCTURAL BLOCK AND MUTUALLY CLUTCHED STRUCTURE BLOCK SYSTEM
MX2020004034A (en) Preparation method for tyrosine kinase inhibitor and intermediate thereof.
CO2018010286A2 (en) Method for protein purification
ES2721672A1 (en) Germanium crystal (Machine-translation by Google Translate, not legally binding)
MX2018005376A (en) Azetidine derivatives for tau imaging.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201030

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5